该前瞻性、随机、多中心试验纳入首次ST段抬高心梗（STEMI）后成功接受经皮冠状动脉介入（PCI）的529例患者，将其随机分入标准治疗组（对照组）和标准治疗联合PCI后3小时单次重组人红细胞生...
基于212个网页-相关网页
段抬高心梗 non-ST elevated myocardial infarction ; NSTEMI
急性ST段抬高心梗 ST-elevation acute coronary infarction
段抬高心肌梗死 STEMI ; ST-segment elevation myocardial infarction ; non-ST-elevation myocardial infarction ; ST elevated acute myocardial infarction
非ST段抬高心梗 non-ST elevated myocardial infarction ; NSTEMI
抬高心肌梗死 NSTEMI ; st-elevation myocardial infarction
段抬高型心肌梗死 NSTEMI ; ST-segment elevation myocardial infarction ; ST-elevation myocardial infarction ; ST-segment elevation myocardion
ST段抬高心肌梗死 ST-segment elevation myocardial infarction ; ST-elevation myocardial infarction ; ST elevation acute myocardial infarction ; STEAMI
抬高的心肌梗死 NSTEMI ; non-ST-segment elevation myocardial infarction ; NSTEM ; Mycardiol infarction
抬高型心梗 STEMI
结果：再灌注治疗是急性ST段抬高心梗治疗的主要方法。
Results: Reperfusion treatment was the major methods on non-ST-elevation acute coronary infarction.
CRUSADE入选包括高危不稳定性心绞痛和非ST段抬高心梗患者。
The CRUSADE initiative included high-risk patients with unstable angina and non–ST-segment elevation myocardial infarction (NSTEMI).
结论：再灌注治疗可以降低急性ST段抬高心梗的住院死亡率，减少住院不良事件的发生。
Conclusion: Reperfusion treatment may reduce the mortality of non-ST-elevation acute coronary infarction and the incidence of events in hospital.
应用推荐